# AZD0120

Source: https://onco.cc/drugs/azd0120/  
OnCo record `azd0120` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AZD0120 is a car-t cell therapy from AstraZeneca, in registered phase 3 trials for multiple myeloma.

## Summary

AZD0120 is listed on ClinicalTrials.gov as an intervention in 2 registered phase 3 trials sponsored by AstraZeneca and Alexion Pharmaceuticals, Inc., in multiple myeloma. A chimeric antigen receptor T-cell therapy, as described in the registry record: the patient's T cells are engineered to recognise a tumour antigen and infused back. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: AZD0120
- Modality: CAR-T cell therapy
- Mechanism: A chimeric antigen receptor T-cell therapy, as described in the registry record: the patient's T cells are engineered to recognise a tumour antigen and infused back.

## Sources

- ClinicalTrials.gov: trials of AZD0120: https://clinicaltrials.gov/search?intr=AZD0120

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- targets: [BCMA](https://onco.cc/targets/bcma/), [CD19](https://onco.cc/targets/cd19/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- trials: [A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela](https://onco.cc/trials/nct07391657/), [AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)](https://onco.cc/trials/nct05850234/), [Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT](https://onco.cc/trials/nct07764978/)

---
JSON: https://onco.cc/api/v1/entities/azd0120.json